NASDAQ:MRKR Marker Therapeutics (MRKR) Stock Price, News & Analysis → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free MRKR Stock Alerts $4.36 -0.04 (-0.91%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$4.33▼$4.5750-Day Range$3.63▼$4.9152-Week Range$0.76▼$9.68Volume3,381 shsAverage Volume18,990 shsMarket Capitalization$38.85 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Marker Therapeutics alerts: Email Address Ad Prosper Trading AcademyThese AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free Copy About Marker Therapeutics Stock (NASDAQ:MRKR)Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells. The company also develops MT-401-OTS, which is in phase 1 clinical trial for the treatment of acute myeloid leukemia; and MT-601 which is in phase 1 clinical trial for the treatment of lymphoma, as well as in phase 1/2 clinical trial for the treatment of pancreatic cancer. Marker Therapeutics is headquartered in Houston, Texas.Read More MRKR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRKR Stock News HeadlinesApril 10, 2024 | investing.comMarker Therapeutics Inc (MRKR)April 9, 2024 | msn.comPutnam Marker Honoring Warner Sisters Restored At Foundry Point ParkApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…April 8, 2024 | globenewswire.comPrincipal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic MalignanciesApril 3, 2024 | finance.yahoo.comGlobal Cardiac Marker Testing Market Sees Robust Growth with Rising Incidence of Cardiovascular DiseasesMarch 26, 2024 | msn.comMarker Therapeutics GAAP EPS of -$1.59, revenue of $3.31MMarch 25, 2024 | globenewswire.comMarker Therapeutics Reports Year-End 2023 Corporate and Financial ResultsMarch 22, 2024 | globenewswire.comMarker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceApril 26, 2024 | True Market Insiders (Ad)The “Next Bitcoin”? 10 CENT Crypto Set to ExplodeThe man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…March 22, 2024 | msn.comJudge Dismisses Lawsuit Over Removal of Marker Dedicated to Communist Party LeaderMarch 14, 2024 | finance.yahoo.comGlobal Marker Pens Market Projected to Reach $492.3 Million by 2030, Driven by a Robust CAGR of 5.2%March 13, 2024 | msn.comEliminate Marker Stains From Brick Surfaces With A Handy Hydrogen Peroxide TrickMarch 12, 2024 | finance.yahoo.comNimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of DirectorsFebruary 16, 2024 | usatoday.comLegislators: Why are women overlooked for Florida's Historical Marker Program?February 3, 2024 | msn.comEXPO Low Odor Dry Erase Marker Starter Set, Now 29% OffJanuary 22, 2024 | finance.yahoo.comMarker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601December 21, 2023 | finance.yahoo.comMarker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”December 12, 2023 | msn.comPSTX, MRKR and GPRO among pre-market losersDecember 11, 2023 | marketwatch.comMarker Therapeutics Shares Rise on Positive MT-601 UpdateDecember 11, 2023 | finance.yahoo.comMarker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T RelapseDecember 4, 2023 | msn.comPICS: Festive style shines at Anantara The Marker Hotel's Christmas tree eventNovember 20, 2023 | msn.comCommunity dedicates Blue/Gold Star Hwy MarkerNovember 15, 2023 | businesswire.comSales Marker Introduces AI Sales to the WorldNovember 10, 2023 | msn.comMarker Therapeutics GAAP EPS of -$0.34, revenue of $257.61MNovember 9, 2023 | morningstar.comMarker Therapeutics Inc MRKRNovember 9, 2023 | finance.yahoo.comMarker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesNovember 8, 2023 | msn.comBlue Star Memorial Highway Marker dedication set for Nov. 9 in Wrightsville BeachSee More Headlines Receive MRKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today4/26/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRKR CUSIPN/A CIK1094038 Webwww.markertherapeutics.com Phone(713) 400-6400FaxN/AEmployees8Year Founded2018Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,240,000.00 Net Margins-142.62% Pretax Margin-424.10% Return on Equity-39.89% Return on Assets-25.45% Debt Debt-to-Equity RatioN/A Current Ratio5.57 Quick Ratio5.57 Sales & Book Value Annual Sales$3.31 million Price / Sales11.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book2.76Miscellaneous Outstanding Shares8,900,000Free Float6,757,000Market Cap$38.85 million OptionableNot Optionable Beta1.50 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Juan F. Vera M.D. (Age 43)Co-Founder, CEO, President, Treasurer & Director Comp: $529.12kMs. Elizabeth DonnellyDirector of AdministrationMr. Edmund CheungVice President of Human ResourcesDr. Nadia Agopyan Ph.D.Senior Vice President of Regulatory AffairsDr. Monic Stuart M.D.Chief Medical OfficerPatricia AllisonHead of Clinical OperationsMr. Michael J. Loiacono (Age 58)Secretary Comp: $287.98kDr. Robert Z. Florkiewicz Sr.Senior Director of Molecular Biology & VirologyMore ExecutivesKey CompetitorsProMIS NeurosciencesNASDAQ:PMNJanOneNASDAQ:JANCara TherapeuticsNASDAQ:CARAOcuphire PharmaNASDAQ:OCUPUnicycive TherapeuticsNASDAQ:UNCYView All Competitors MRKR Stock Analysis - Frequently Asked Questions How have MRKR shares performed in 2024? Marker Therapeutics' stock was trading at $5.50 on January 1st, 2024. Since then, MRKR stock has decreased by 20.6% and is now trading at $4.3650. View the best growth stocks for 2024 here. Are investors shorting Marker Therapeutics? Marker Therapeutics saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 64,400 shares, a decline of 40.3% from the March 31st total of 107,900 shares. Based on an average daily volume of 18,700 shares, the short-interest ratio is presently 3.4 days. Currently, 1.0% of the company's stock are sold short. View Marker Therapeutics' Short Interest. When is Marker Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our MRKR earnings forecast. How were Marker Therapeutics' earnings last quarter? Marker Therapeutics, Inc. (NASDAQ:MRKR) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.01. Marker Therapeutics had a negative trailing twelve-month return on equity of 39.89% and a negative net margin of 142.62%. What other stocks do shareholders of Marker Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), Flexion Therapeutics (FLXN), Geron (GERN) and Ionis Pharmaceuticals (IONS). How do I buy shares of Marker Therapeutics? Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRKR) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
